Pro Medicus Stock Forecast, Price & News

0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $35.65
50-Day Range
MA: $33.82
52-Week Range
Now: $35.65
Average Volume1,263 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions in Australia, Europe, and North America. It offers medical software for practice management; integration products; Promedicus.net secure email; healthcare software that provides radiologist and clinicians with advanced visualization capability for viewing 2-D, 3-D, and 4-D medical images; and PACS/Digital imaging software. The company offers its products under the Visage RIS, Visage RIS/PACS, and Visage 7 names. It also provides Visage Ease Pro, a mobile applications, which allow users access to medical imaging results that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company offers its products and services to hospitals, diagnostic imaging groups, and other health related entities. Pro Medicus Limited was founded in 1983 and is headquartered in Richmond, Australia.
Pro Medicus logo

Industry, Sector and Symbol

Industry Health Information Services
Phone61 3 9429 8800
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable


How Is Pro Medicus' (ASX:PME) CEO Compensated?
January 1, 2021 |  finance.yahoo.com
Are Insiders Buying Pro Medicus Limited (ASX:PME) Stock?
September 15, 2020 |  finance.yahoo.com
Is Pro Medicus Limited's (ASX:PME) CEO Pay Fair?
February 22, 2020 |  finance.yahoo.com
UK Stocks-Factors to watch on Dec. 20
December 20, 2019 |  feeds.reuters.com
See More Headlines


Overall MarketRank

0.52 out of 5 stars

Computer And Technology Sector

1078th out of 1,551 stocks

Health Information Services Industry

9th out of 15 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PMCUF News and Ratings via Email

Sign-up to receive the latest news and ratings for PMCUF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Pro Medicus (OTCMKTS:PMCUF) Frequently Asked Questions

Is Pro Medicus a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pro Medicus in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Pro Medicus stock.
View analyst ratings for Pro Medicus
or view top-rated stocks.

What stocks does MarketBeat like better than Pro Medicus?

Wall Street analysts have given Pro Medicus a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pro Medicus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pro Medicus?

Pro Medicus saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 1,600 shares, a drop of 80.2% from the March 15th total of 8,100 shares. Based on an average daily volume of 200 shares, the short-interest ratio is currently 8.0 days.
View Pro Medicus' Short Interest

How has Pro Medicus' stock been impacted by COVID-19?

Pro Medicus' stock was trading at $11.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PMCUF stock has increased by 205.0% and is now trading at $35.6510.
View which stocks have been most impacted by COVID-19

Who are Pro Medicus' key executives?

Pro Medicus' management team includes the following people:
  • Dr. Sam Aaron Hupert M.D., M.B.B.S., Co-Founder, CEO, MD & Exec. Director
  • Mr. Anthony Barry Hall B.Sc., B.Sc.(Hons), M.Sc., Co-Founder, Technology Director & Exec. Director
  • Dr. Malte Westerhoff, GM of Europe & Global CTO
  • Mr. Brad Levin, GM of North America & Global Head of Marketing
  • Mr. Sean Lambright, Global Head of Sales - Visage Imaging Inc
  • Mr. Clayton James Hatch CPA, B.Comm, CPA, CFO & Company Sec.

Who are some of Pro Medicus' key competitors?

What is Pro Medicus' stock symbol?

Pro Medicus trades on the OTCMKTS under the ticker symbol "PMCUF."

How do I buy shares of Pro Medicus?

Shares of PMCUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pro Medicus' stock price today?

One share of PMCUF stock can currently be purchased for approximately $35.65.

What is Pro Medicus' official website?

The official website for Pro Medicus is www.promed.com.au.

How can I contact Pro Medicus?

The company can be reached via phone at 61 3 9429 8800.

This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.